JP6605446B2 - 形質移入用の脂質ナノ粒子および関連方法 - Google Patents

形質移入用の脂質ナノ粒子および関連方法 Download PDF

Info

Publication number
JP6605446B2
JP6605446B2 JP2016502986A JP2016502986A JP6605446B2 JP 6605446 B2 JP6605446 B2 JP 6605446B2 JP 2016502986 A JP2016502986 A JP 2016502986A JP 2016502986 A JP2016502986 A JP 2016502986A JP 6605446 B2 JP6605446 B2 JP 6605446B2
Authority
JP
Japan
Prior art keywords
lipid
sirna
streams
channel
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016502986A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016515815A (ja
JP2016515815A5 (cg-RX-API-DMAC10.html
Inventor
ラムセイ、ユーアン
テイラー、アール.・ジェームズ
ワルシュ、コリン
ベリービュー、ネイサン・エム.
カリース、ピーター・アール.
リーバー、ティモシー
ワイルド、アンドレ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Publication of JP2016515815A publication Critical patent/JP2016515815A/ja
Publication of JP2016515815A5 publication Critical patent/JP2016515815A5/ja
Application granted granted Critical
Publication of JP6605446B2 publication Critical patent/JP6605446B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
JP2016502986A 2013-03-15 2014-03-14 形質移入用の脂質ナノ粒子および関連方法 Active JP6605446B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361798495P 2013-03-15 2013-03-15
US61/798,495 2013-03-15
PCT/US2014/029116 WO2014172045A1 (en) 2013-03-15 2014-03-14 Lipid nanoparticles for transfection and related methods

Publications (3)

Publication Number Publication Date
JP2016515815A JP2016515815A (ja) 2016-06-02
JP2016515815A5 JP2016515815A5 (cg-RX-API-DMAC10.html) 2017-04-06
JP6605446B2 true JP6605446B2 (ja) 2019-11-13

Family

ID=51731753

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016502986A Active JP6605446B2 (ja) 2013-03-15 2014-03-14 形質移入用の脂質ナノ粒子および関連方法

Country Status (6)

Country Link
US (2) US10342760B2 (cg-RX-API-DMAC10.html)
EP (1) EP2971013B1 (cg-RX-API-DMAC10.html)
JP (1) JP6605446B2 (cg-RX-API-DMAC10.html)
CN (1) CN105143456A (cg-RX-API-DMAC10.html)
CA (1) CA2906732C (cg-RX-API-DMAC10.html)
WO (1) WO2014172045A1 (cg-RX-API-DMAC10.html)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
HRP20220070T1 (hr) 2014-04-23 2022-04-01 Modernatx, Inc. Cjepiva nukleinske kiseline
CN106794141B (zh) * 2014-07-16 2021-05-28 诺华股份有限公司 将核酸包封在脂质纳米粒主体中的方法
WO2016138175A1 (en) 2015-02-24 2016-09-01 The University Of British Columbia Continuous flow microfluidic system
EP4353257A3 (en) 2015-04-13 2024-08-07 CureVac Manufacturing GmbH Method for producing rna compositions
USD771833S1 (en) 2015-04-28 2016-11-15 University Of British Columbia Microfluidic cartridge
USD772427S1 (en) 2015-04-28 2016-11-22 University Of British Columbia Microfluidic cartridge
CN107921381B (zh) * 2015-04-28 2021-11-09 不列颠哥伦比亚大学 一次性微流控盒
USD771834S1 (en) 2015-04-28 2016-11-15 University Of British Columbia Microfluidic cartridge
EP3328394A4 (en) 2015-07-30 2019-03-13 ModernaTX, Inc. CONCATEMEE peptide epitope RNAs
HRP20220156T1 (hr) 2015-09-17 2022-04-15 Modernatx, Inc. Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava
EP3364949A4 (en) 2015-10-22 2019-07-31 ModernaTX, Inc. CANCER VACCINES
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
EP3364981A4 (en) 2015-10-22 2019-08-07 ModernaTX, Inc. VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
DE20164728T1 (de) 2015-10-22 2021-09-30 Modernatx, Inc. Impfstoffe gegen atemwegsvirus
DK3386484T3 (da) * 2015-12-10 2022-07-04 Modernatx Inc Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler
RS63051B1 (sr) 2015-12-22 2022-04-29 Modernatx Inc Jedinjenja i kompozicije za intracelularnu isporuku agenasa
WO2017117647A1 (en) 2016-01-06 2017-07-13 The University Of British Columbia Bifurcating mixers and methods of their use and manufacture
CN105622473B (zh) * 2016-02-06 2017-07-25 吴国球 一种阳离子氨基脂质及其合成方法和用途
JP7114485B2 (ja) 2016-05-18 2022-08-08 モデルナティエックス インコーポレイテッド ファブリー病の治療のためのα-ガラクトシダーゼAをコードするポリヌクレオチド
EP3468537A1 (en) 2016-06-14 2019-04-17 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
US11059039B2 (en) 2016-07-06 2021-07-13 Precision Nanosystems Inc. Smart microfluidic mixing instrument and cartridges
WO2018064755A1 (en) * 2016-10-03 2018-04-12 Precision Nanosystems Inc. Compositions for transfecting resistant cell types
EP3528821A4 (en) 2016-10-21 2020-07-01 ModernaTX, Inc. HUMAN CYTOMEGALOVIRUS VACCINE
EP3538067A1 (en) 2016-11-08 2019-09-18 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
MA46766A (fr) 2016-11-11 2019-09-18 Modernatx Inc Vaccin antigrippal
RS63953B1 (sr) 2017-03-15 2023-02-28 Modernatx Inc Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava
WO2018170322A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Crystal forms of amino lipids
WO2018170260A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Respiratory syncytial virus vaccine
JP7332478B2 (ja) * 2017-03-15 2023-08-23 モデルナティエックス インコーポレイテッド 脂質ナノ粒子製剤
MA48047A (fr) 2017-04-05 2020-02-12 Modernatx Inc Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée
EP3638678B1 (en) 2017-06-14 2025-12-03 ModernaTX, Inc. Compounds and compositions for intracellular delivery of agents
MA49421A (fr) 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
CN107488137B (zh) * 2017-08-15 2019-03-29 浙江大学 一种小分子量的季铵盐及其制备方法和应用
MX2020002348A (es) * 2017-08-31 2020-10-08 Modernatx Inc Métodos de elaboración de nanopartículas lipídicas.
EP3688162B1 (en) * 2017-09-29 2024-03-06 Intellia Therapeutics, Inc. Formulations
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
ES3001512T3 (en) 2018-04-29 2025-03-05 Global Life Sciences Solutions Canada Ulc Compositions for transfecting resistant cell types
EP3853202A1 (en) 2018-09-19 2021-07-28 ModernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
US12151029B2 (en) 2018-09-19 2024-11-26 Modernatx, Inc. PEG lipids and uses thereof
CN112996854B (zh) * 2018-09-19 2024-08-30 摩登纳特斯有限公司 高纯度peg脂质和其用途
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
DK3864163T3 (da) * 2018-10-09 2024-05-06 Univ British Columbia Sammensætninger og systemer omfattende transfektionskompetente vesikler fri for organiske opløsningsmidler og rengøringsmidler og fremgangsmåder forbundet dermed
CN113939282A (zh) 2019-01-31 2022-01-14 摩登纳特斯有限公司 制备脂质纳米颗粒的方法
KR20210133218A (ko) * 2019-01-31 2021-11-05 모더나티엑스, 인크. 볼텍스 믹서 및 연계된 방법, 시스템 및 이의 장치
KR102732019B1 (ko) * 2019-04-15 2024-11-20 글로벌 라이프 사이언시즈 솔루션즈 캐나다 유엘씨 T 세포 유전자 발현의 비바이러스 변형
JP7416096B2 (ja) 2019-06-20 2024-01-17 プレシジョン ナノシステムズ ユーエルシー 核酸送達のためのイオン化可能な脂質
KR102928289B1 (ko) 2019-06-29 2026-02-20 글로벌 라이프 사이언시즈 솔루션즈 캐나다 유엘씨 핵산 전달을 위한 이온화 가능한 지질
AU2020351220A1 (en) 2019-09-19 2022-04-07 Modernatx, Inc. Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents
EP4031524A1 (en) 2019-09-19 2022-07-27 ModernaTX, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
CN115778904B (zh) * 2019-10-29 2025-03-28 珠海丽凡达生物技术有限公司 一种用于体外转染和体内递送mRNA的制剂
US20230285297A1 (en) 2020-01-31 2023-09-14 Modernatx, Inc. Methods of preparing lipid nanoparticles
CN118490818A (zh) 2020-04-22 2024-08-16 生物技术欧洲股份公司 冠状病毒疫苗
EP3915544A1 (en) * 2020-05-25 2021-12-01 Leon-Nanodrugs GmbH Method for producing a liposome dispersion
GB202011367D0 (en) * 2020-07-22 2020-09-02 Micropore Tech Limited Method of preparing liposomes
WO2022032154A2 (en) 2020-08-06 2022-02-10 Modernatx, Inc. Compositions for the delivery of payload molecules to airway epithelium
TW202220637A (zh) 2020-08-06 2022-06-01 美商現代公司 製備脂質奈米顆粒之方法
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
CA3199784A1 (en) 2020-11-13 2022-05-19 Modernatx, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
DE102020214601A1 (de) 2020-11-19 2022-05-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung eingetragener Verein Verfahren und Vorrichtung zur Herstellung einer Flüssigkeit enthaltend Liposomen und hergestellte Flüssigkeit
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
EP4346901A4 (en) * 2021-06-01 2025-04-23 The University of British Columbia MRNA DELIVERY USING LIPID NANOPARTICLES
WO2023009422A1 (en) 2021-07-26 2023-02-02 Modernatx, Inc. Processes for preparing lipid nanoparticle compositions for the delivery of payload molecules to airway epithelium
WO2023009421A1 (en) 2021-07-26 2023-02-02 Modernatx, Inc. Processes for preparing lipid nanoparticle compositions
JP7689238B2 (ja) 2021-07-27 2025-06-05 エスケー バイオサイエンス カンパニー リミテッド タンパク質発現のためのmRNA、及びそのためのテンプレート
CN115671294A (zh) * 2021-07-27 2023-02-03 中国医学科学院基础医学研究所 St类脂质化合物在制备核酸递送试剂中的应用及相关产品
US20260109732A1 (en) 2021-10-29 2026-04-23 Modernatx, Inc. Lipid amines
EP4429644A1 (en) 2021-11-12 2024-09-18 ModernaTX, Inc. Compositions for the delivery of payload molecules to airway epithelium
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
TW202345863A (zh) 2022-02-09 2023-12-01 美商現代公司 黏膜投與方法及調配物
CA3247022A1 (en) * 2022-03-28 2025-07-08 National University Corporation Chiba University METHOD FOR PRODUCING LIPID NANOPARTICLES ENCAPSULATED IN A NUCLEIC ACID, METHOD FOR PRODUCING A PHARMACEUTICAL COMPOSITION CONTAINING SAID LIPID NANOPARTICLES, AND METHOD FOR INTRODUCING NUCLEIC ACID INTO A CELL OR A TARGET CELL
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
IT202200016386A1 (it) * 2022-08-02 2024-02-02 Univ Degli Studi Roma La Sapienza Nanoparticelle lipidiche multicomponenti ad elevata fusogenicità cellulare per la veicolazione di acidi nucleici e relativo processo di preparazione
WO2024197404A1 (en) * 2023-03-30 2024-10-03 Ho Emmanuel Abraham Bacteria-responsive particles, methods for preparation, and use in packaging or on surfaces
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
CN117070570A (zh) * 2023-08-28 2023-11-17 南通大学 提高脂质体转染试剂的转染效率的方法
EP4516295A1 (en) * 2023-09-04 2025-03-05 ETH Zurich Ph-inducible structure-switching lipid nanovectors, semi-synthetic extracellular vesicles, methods of making same and uses thereof
CN121909024A (zh) * 2023-09-22 2026-04-21 国立大学法人东北大学 包封有核酸的配体修饰脂质纳米颗粒的制造方法
EP4759139A1 (en) * 2024-12-16 2026-06-17 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Nucleid acid surfactant particle composition for the control of pest- and vector arthropods

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
CN1173776C (zh) 1996-06-28 2004-11-03 卡钳技术有限公司 在微规模流体性设备里的高通过量的筛选分析系统
EP1030733A1 (en) 1997-02-05 2000-08-30 California Institute Of Technology Microfluidic sub-millisecond mixers
US6835395B1 (en) 1997-05-14 2004-12-28 The University Of British Columbia Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
CA2289702C (en) 1997-05-14 2008-02-19 Inex Pharmaceuticals Corp. High efficiency encapsulation of charged therapeutic agents in lipid vesicles
ATE397488T1 (de) * 1998-11-13 2008-06-15 Heriot William A Vorrichtung zur herstellung von liposomen
EP1203614A1 (de) 2000-11-03 2002-05-08 Polymun Scientific Immunbiologische Forschung GmbH Verfahren und Vorrichtung zur Herstellung von Lipidvesikeln
US8137699B2 (en) 2002-03-29 2012-03-20 Trustees Of Princeton University Process and apparatuses for preparing nanoparticle compositions with amphiphilic copolymers and their use
WO2002087541A1 (en) 2001-04-30 2002-11-07 Protiva Biotherapeutics Inc. Lipid-based formulations for gene transfer
EP1412065A2 (en) 2001-07-27 2004-04-28 President And Fellows Of Harvard College Laminar mixing apparatus and methods
US7252928B1 (en) 2002-03-12 2007-08-07 Caliper Life Sciences, Inc. Methods for prevention of surface adsorption of biological materials to capillary walls in microchannels
US7901939B2 (en) 2002-05-09 2011-03-08 University Of Chicago Method for performing crystallization and reactions in pressure-driven fluid plugs
CA2752143C (en) 2002-05-15 2014-09-23 Sutter West Bay Hospitals Delivery of nucleic acid-like compounds
EP1519714B1 (en) 2002-06-28 2010-10-20 Protiva Biotherapeutics Inc. Method and apparatus for producing liposomes
JP2006507921A (ja) 2002-06-28 2006-03-09 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 流体分散のための方法および装置
US7214348B2 (en) 2002-07-26 2007-05-08 Applera Corporation Microfluidic size-exclusion devices, systems, and methods
JP2007524604A (ja) 2003-03-31 2007-08-30 アルザ・コーポレーシヨン 非対称の脂質被膜を有する脂質粒子およびその製造方法
US7160025B2 (en) 2003-06-11 2007-01-09 Agency For Science, Technology And Research Micromixer apparatus and methods of using same
US7745221B2 (en) 2003-08-28 2010-06-29 Celula, Inc. Methods and apparatus for sorting cells using an optical switch in a microfluidic channel network
CN1882693B (zh) 2003-09-15 2012-08-15 普洛体维生物治疗公司 聚乙二醇修饰的脂质化合物及其应用
US20050175683A1 (en) 2003-10-24 2005-08-11 Yuanpeng Zhang Preparation of lipid particles
EP1537858A1 (en) 2003-12-04 2005-06-08 Vectron Therapeutics AG Drug delivery vehicles and uses thereof
US7507380B2 (en) 2004-03-19 2009-03-24 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Microchemical nanofactories
AU2005251691A1 (en) 2004-05-17 2005-12-22 Tekmira Pharmaceuticals Corporation Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
US7745651B2 (en) 2004-06-07 2010-06-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
US7871632B2 (en) 2004-07-12 2011-01-18 Adventrx Pharmaceuticals, Inc. Compositions for delivering highly water soluble drugs
AU2005281352B2 (en) 2004-09-09 2011-01-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal compositions of glucocorticoid and glucocorticoid derivatives
EP1804964A1 (en) 2004-10-01 2007-07-11 Velocys Inc. Multiphase mixing process using microchannel process technology
EP1679115A1 (en) 2005-01-07 2006-07-12 Corning Incorporated High performance microreactor
WO2006102675A1 (en) 2005-03-23 2006-09-28 Velocys, Inc. Surface features in microprocess technology
US20060219307A1 (en) 2005-03-31 2006-10-05 National Taiwan University Micromixer apparatus and method therefor
JP5639338B2 (ja) 2005-07-27 2014-12-10 プロチバ バイオセラピューティクス インコーポレイティッド リポソームの製造システムおよび製造方法
EP1934246B8 (en) 2005-10-07 2012-02-08 Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. Matrix metalloproteinase 11 vaccine
US20070087045A1 (en) * 2005-10-14 2007-04-19 Industrial Technology Research Institute Lipid carrier and method of preparing the same
JP2007252979A (ja) 2006-03-20 2007-10-04 National Institute Of Advanced Industrial & Technology マイクロリアクタによる化合物の製造方法、そのマイクロリアクタ、及びマイクロリアクタ用の分流器
US7794136B2 (en) 2006-05-09 2010-09-14 National Tsing Hua University Twin-vortex micromixer for enforced mass exchange
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
WO2008053988A1 (fr) 2006-11-02 2008-05-08 National University Corporation Nagoya University Procédé de production de microcapsules
CN101209243B (zh) 2006-12-29 2010-12-08 石药集团中奇制药技术(石家庄)有限公司 一种脂质体药物及其制备方法
WO2008151022A2 (en) 2007-05-31 2008-12-11 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
WO2009002152A1 (en) 2007-06-26 2008-12-31 Micronit Microfluidics B.V. Device and method for fluidic coupling of fluidic conduits to a microfluidic chip, and uncoupling thereof
EP3100718B1 (en) 2008-01-02 2019-11-27 Arbutus Biopharma Corporation Improved compositions and methods for the delivery of nucleic acids
US8414182B2 (en) 2008-03-28 2013-04-09 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Micromixers for nanomaterial production
EP2279254B1 (en) 2008-04-15 2017-07-05 Protiva Biotherapeutics Inc. Novel lipid formulations for nucleic acid delivery
US8187554B2 (en) 2008-04-23 2012-05-29 Microfluidics International Corporation Apparatus and methods for nanoparticle generation and process intensification of transport and reaction systems
US20110182994A1 (en) 2008-07-25 2011-07-28 S.K. Pharmaceuticals, Inc. Methods and systems for production of nanoparticles
EP3699172A3 (en) 2008-11-10 2020-11-18 Arbutus Biopharma Corporation Novel lipids and compositions for the delivery of therapeutics
EP2391343B1 (en) * 2009-01-29 2017-03-01 Arbutus Biopharma Corporation Improved lipid formulation for the delivery of nucleic acids
KR20220038506A (ko) * 2009-06-10 2022-03-28 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
US9029338B2 (en) * 2009-08-14 2015-05-12 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
CA2781529C (en) 2009-09-23 2017-10-24 Indu Javeri Methods for the preparation of liposomes comprising docetaxel
RU2573409C2 (ru) * 2009-11-04 2016-01-20 Дзе Юниверсити Оф Бритиш Коламбиа Содержащие нуклеиновые кислоты липидные частицы и относящиеся к ним способы
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
WO2012016184A2 (en) * 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
US8361415B2 (en) 2010-09-13 2013-01-29 The Regents Of The University Of California Inertial particle focusing system

Also Published As

Publication number Publication date
CA2906732C (en) 2023-08-08
EP2971013A1 (en) 2016-01-20
CN105143456A (zh) 2015-12-09
JP2016515815A (ja) 2016-06-02
EP2971013B1 (en) 2020-08-19
US10342760B2 (en) 2019-07-09
EP2971013A4 (en) 2016-10-19
US20190307689A1 (en) 2019-10-10
US20160022580A1 (en) 2016-01-28
CA2906732A1 (en) 2014-10-23
WO2014172045A8 (en) 2015-10-15
WO2014172045A1 (en) 2014-10-23

Similar Documents

Publication Publication Date Title
US20190307689A1 (en) Lipid nanoparticles for transfection and related methods
US20230235359A1 (en) Nucleic acid-containing lipid particles and related methods
US12611640B2 (en) Continuous flow microfluidic system
US10159652B2 (en) Device for formulating particles at small volumes
US20200269201A1 (en) Bifurcating mixers and methods of their use and manufacture
CN113710811A (zh) T细胞基因表达的非病毒修饰

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150918

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170301

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20171019

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180820

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190426

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190917

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191016

R150 Certificate of patent or registration of utility model

Ref document number: 6605446

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250